Sei Hyun Ahn
YOU?
Author Swipe
View article: Prognostic Value of Neutrophil-Lymphocyte Ratio Change After Short-Term Chemotherapy in <i>De Novo</i> Stage IV Breast Cancer Patients
Prognostic Value of Neutrophil-Lymphocyte Ratio Change After Short-Term Chemotherapy in <i>De Novo</i> Stage IV Breast Cancer Patients Open
We aimed to investigate whether the neutrophil-to-lymphocyte ratio (NLR) change after the first cycle of palliative chemotherapy can be a prognostic indicator in de novo stage IV breast cancer. We retrospectively reviewed 218 patients trea…
View article: Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Open
Patients with HER2-low tumors had no significant difference in pCR rate compared to HER2-zero but showed better survival, especially in HorR-negative tumors. Further investigation into biological differences is warranted.
View article: Survival pattern in male breast cancer: distinct from female breast cancer
Survival pattern in male breast cancer: distinct from female breast cancer Open
Introduction Male breast cancer (MBC) is a rare condition, and recent research has underscored notable distinctions between MBC and breast cancer in women. This study aimed to assess and contrast the long-term survival outcomes and disease…
View article: Factors in Parenting Stress in Young Patients With Breast Cancer and Implications for Children’s Emotional Development
Factors in Parenting Stress in Young Patients With Breast Cancer and Implications for Children’s Emotional Development Open
Importance The number of patients with breast cancer who have children is substantial. However, the emotional burden of this disease and its implication for childhood development remain largely unknown. Objective To investigate the clinica…
View article: Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer Open
Importance Both high 21-gene recurrence score (RS) and high Ki-67 level are poor prognostic factors in patients with estrogen receptor (ER)–positive ERBB2 -negative (ER+/ ERBB− ) breast cancer; however, a discrepancy between the 2 has been…
View article: The Impact of a Mobile Support Group on Distress and Physical Activity in Breast Cancer Survivors: Randomized, Parallel-Group, Open-Label, Controlled Trial
The Impact of a Mobile Support Group on Distress and Physical Activity in Breast Cancer Survivors: Randomized, Parallel-Group, Open-Label, Controlled Trial Open
Background While mobile health apps have demonstrated their potential in revolutionizing health behavior changes, the impact of a mobile community built on these apps on the level of physical activity and mental well-being in cancer surviv…
View article: Supplementary Tables 1 - 2 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Tables 1 - 2 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
PDF file, 72K, S1: Clinical safety laboratory parameters; S2: Tissue distribution of 18FFSPG.
View article: Supplementary Figure Legend from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Figure Legend from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
PDF file, 76K, includes movie legends.
View article: Supplementary Movie 2A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 2A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 146K, Maximum intensity projection of 18FFDG in a breast cancer patient (Patient 13).
View article: Supplementary Movie 1A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 1A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 167K, Maximum intensity projection of 18FFDG in a lung cancer patient (Patient 2).
View article: Supplementary Movie 1B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 1B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 180K, Maximum intensity projection of 18FFSPG in a lung cancer patient (Patient 2).
View article: Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
PDF file, 358K, S1: System xC� and CD44 in glutathione biosynthesis and the cysteine-cystine redox cycle; S2: 18FFSPG distribution in normal organs and cancer; S3: Correlation between 18FFDG and 18FFSPG; S4: 18FFDG and 18FFSPG PET in a bre…
View article: Supplementary Movie 1A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 1A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 167K, Maximum intensity projection of 18FFDG in a lung cancer patient (Patient 2).
View article: Data from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Data from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
Purpose: (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (BAY 94-9392, alias [18F]FSPG) is a new tracer to image xC− transporter activity with positron emission tomography (PET). We aimed to explore the tumor detection rate of [18F]FSPG in patien…
View article: Supplementary Figure Legend from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Figure Legend from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
PDF file, 76K, includes movie legends.
View article: Supplementary Movie 1B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 1B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 180K, Maximum intensity projection of 18FFSPG in a lung cancer patient (Patient 2).
View article: Supplementary Movie 2B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 2B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 161K, Maximum intensity projection of 18FFSPG in a breast cancer patient (Patient 13).
View article: Supplementary Tables 1 - 2 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Tables 1 - 2 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
PDF file, 72K, S1: Clinical safety laboratory parameters; S2: Tissue distribution of 18FFSPG.
View article: Data from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Data from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
Purpose: (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (BAY 94-9392, alias [18F]FSPG) is a new tracer to image xC− transporter activity with positron emission tomography (PET). We aimed to explore the tumor detection rate of [18F]FSPG in patien…
View article: Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
PDF file, 358K, S1: System xC� and CD44 in glutathione biosynthesis and the cysteine-cystine redox cycle; S2: 18FFSPG distribution in normal organs and cancer; S3: Correlation between 18FFDG and 18FFSPG; S4: 18FFDG and 18FFSPG PET in a bre…
View article: Supplementary Movie 2A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 2A from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 146K, Maximum intensity projection of 18FFDG in a breast cancer patient (Patient 13).
View article: Supplementary Movie 2B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Supplementary Movie 2B from Exploratory Clinical Trial of (4<i>S</i>)-4-(3-[<sup>18</sup>F]fluoropropyl)-l-glutamate for Imaging x<sub>C</sub><sup>−</sup> Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open
AVI, 161K, Maximum intensity projection of 18FFSPG in a breast cancer patient (Patient 13).
View article: The Impact of a Mobile Support Group on Distress and Physical Activity in Breast Cancer Survivors: Randomized, Parallel-Group, Open-Label, Controlled Trial (Preprint)
The Impact of a Mobile Support Group on Distress and Physical Activity in Breast Cancer Survivors: Randomized, Parallel-Group, Open-Label, Controlled Trial (Preprint) Open
BACKGROUND While mobile health apps have demonstrated their potential in revolutionizing health behavior changes, the impact of a mobile community built on these apps on the level of physical activity and mental well-being in cancer survi…
View article: Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, <i>ERBB2</i>–Negative Breast Cancer
Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, <i>ERBB2</i>–Negative Breast Cancer Open
Importance Body mass index (BMI) may affect the 21-gene recurrence score (RS) in patients with ER-positive, ERBB2 -negative breast cancer. If high BMI increases genomic risk in ER-positive, ERBB2 -negative breast cancer, weight control wil…
View article: Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer Open
Purpose MammaPrint (MMP) helps clinicians identify the ideal time for adjuvant treatment for patients with early HR+/HER2- breast cancer. We aimed to externally validate a nomogram designed to predict probability of low risk of MMP results…
View article: Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer
Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer Open
We examined whether 18 F-fluorodeoxyglucose metabolism is associated with distant relapse-free survival (DRFS) and overall survival (OS) in women with estrogen receptor (ER)-positive, HER2-negative breast cancer. This was a cohort study ex…
View article: Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence
Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence Open
Purpose To evaluate the clinical course and long-term outcomes of patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) and identify independent prognostic factors for further recurrence. Methods In…
View article: Is There a Difference in the Diagnosis and Prognosis of Local Recurrence between Autologous Tissue and Implant-Based Breast Reconstruction?
Is There a Difference in the Diagnosis and Prognosis of Local Recurrence between Autologous Tissue and Implant-Based Breast Reconstruction? Open
Introduction. Breast reconstruction has become common after total mastectomy; however, certain types of breast reconstruction may be associated with delayed local recurrence or poor survival. Here, we investigated whether there are differe…